Elocalcitol is a calcitriol analog for inhibition of prostate cell growth; in phase II clinical trial in patients with benign prostate hyperplasia (4/2004).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aluminum hydroxide | The serum concentration of Aluminum hydroxide can be increased when it is combined with Elocalcitol. |
| Danazol | Danazol may increase the hypercalcemic activities of Elocalcitol. |
| Sucralfate | The serum concentration of Sucralfate can be increased when it is combined with Elocalcitol. |
| Orlistat | Orlistat can cause a decrease in the absorption of Elocalcitol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium sulfate | The serum concentration of Magnesium sulfate can be increased when it is combined with Elocalcitol. |
| Magnesium oxide | The serum concentration of Magnesium oxide can be increased when it is combined with Elocalcitol. |
| Magnesium salicylate | The serum concentration of Magnesium salicylate can be increased when it is combined with Elocalcitol. |
| Magaldrate | The serum concentration of Magaldrate can be increased when it is combined with Elocalcitol. |
| Magnesium hydroxide | The serum concentration of Magnesium hydroxide can be increased when it is combined with Elocalcitol. |
| Magnesium trisilicate | The serum concentration of Magnesium trisilicate can be increased when it is combined with Elocalcitol. |
| Magnesium chloride | The serum concentration of Magnesium chloride can be increased when it is combined with Elocalcitol. |
| Magnesium carbonate | The serum concentration of Magnesium carbonate can be increased when it is combined with Elocalcitol. |
| Talc | The serum concentration of Talc can be increased when it is combined with Elocalcitol. |
| Magnesium citrate | The serum concentration of Magnesium citrate can be increased when it is combined with Elocalcitol. |
| Magnesium silicate | The serum concentration of Magnesium silicate can be increased when it is combined with Elocalcitol. |
| Hydrotalcite | The serum concentration of Hydrotalcite can be increased when it is combined with Elocalcitol. |
| Magnesium aspartate | The serum concentration of Magnesium aspartate can be increased when it is combined with Elocalcitol. |
| Magnesium peroxide | The serum concentration of Magnesium peroxide can be increased when it is combined with Elocalcitol. |
| Magnesium gluconate | The serum concentration of Magnesium gluconate can be increased when it is combined with Elocalcitol. |
| Magnesium orotate | The serum concentration of Magnesium orotate can be increased when it is combined with Elocalcitol. |
| Magnesium | The serum concentration of Magnesium can be increased when it is combined with Elocalcitol. |
| Magnesium levulinate | The serum concentration of Magnesium levulinate can be increased when it is combined with Elocalcitol. |
| Magnesium lactate | The serum concentration of Magnesium lactate can be increased when it is combined with Elocalcitol. |
| Digoxin | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Elocalcitol is combined with Digoxin. |
| Acetyldigitoxin | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Elocalcitol is combined with Acetyldigitoxin. |
| Deslanoside | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Elocalcitol is combined with Deslanoside. |
| Ouabain | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Elocalcitol is combined with Ouabain. |
| Digitoxin | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Elocalcitol is combined with Digitoxin. |
| Oleandrin | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Elocalcitol is combined with Oleandrin. |
| Cymarin | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Elocalcitol is combined with Cymarin. |
| Proscillaridin | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Elocalcitol is combined with Proscillaridin. |
| Metildigoxin | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Elocalcitol is combined with Metildigoxin. |
| Lanatoside C | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Elocalcitol is combined with Lanatoside C. |
| Gitoformate | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Elocalcitol is combined with Gitoformate. |
| Acetyldigoxin | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Elocalcitol is combined with Acetyldigoxin. |
| Peruvoside | The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Elocalcitol is combined with Peruvoside. |
| Mineral oil | Mineral oil can cause a decrease in the absorption of Elocalcitol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methyclothiazide | The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Elocalcitol. |
| Bendroflumethiazide | The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Elocalcitol. |
| Benzthiazide | The risk or severity of hypercalcemia can be increased when Benzthiazide is combined with Elocalcitol. |
| Cyclothiazide | The risk or severity of hypercalcemia can be increased when Cyclothiazide is combined with Elocalcitol. |
| Hydroflumethiazide | The risk or severity of hypercalcemia can be increased when Hydroflumethiazide is combined with Elocalcitol. |
| Chlorothiazide | The risk or severity of hypercalcemia can be increased when Chlorothiazide is combined with Elocalcitol. |
| Hydrochlorothiazide | The risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Elocalcitol. |
| Trichlormethiazide | The risk or severity of hypercalcemia can be increased when Trichlormethiazide is combined with Elocalcitol. |
| Polythiazide | The risk or severity of hypercalcemia can be increased when Polythiazide is combined with Elocalcitol. |
| Mebutizide | The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Elocalcitol. |
| Cyclopenthiazide | The risk or severity of hypercalcemia can be increased when Cyclopenthiazide is combined with Elocalcitol. |
| Buthiazide | The risk or severity of hypercalcemia can be increased when Buthiazide is combined with Elocalcitol. |
| Calcitriol | The risk or severity of adverse effects can be increased when Calcitriol is combined with Elocalcitol. |
| Calcifediol | The risk or severity of adverse effects can be increased when Calcifediol is combined with Elocalcitol. |
| Ergocalciferol | The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Elocalcitol. |
| Cholecalciferol | The risk or severity of adverse effects can be increased when Cholecalciferol is combined with Elocalcitol. |
| Paricalcitol | The risk or severity of adverse effects can be increased when Paricalcitol is combined with Elocalcitol. |
| Dihydrotachysterol | The risk or severity of adverse effects can be increased when Dihydrotachysterol is combined with Elocalcitol. |
| Alfacalcidol | The risk or severity of adverse effects can be increased when Alfacalcidol is combined with Elocalcitol. |
| Seocalcitol | The risk or severity of adverse effects can be increased when Seocalcitol is combined with Elocalcitol. |
| Inecalcitol | The risk or severity of adverse effects can be increased when Inecalcitol is combined with Elocalcitol. |
| Becocalcidiol | The risk or severity of adverse effects can be increased when Becocalcidiol is combined with Elocalcitol. |
| Eldecalcitol | The risk or severity of adverse effects can be increased when Eldecalcitol is combined with Elocalcitol. |
| 1alpha,24S-Dihydroxyvitamin D2 | The risk or severity of adverse effects can be increased when 1alpha,24S-Dihydroxyvitamin D2 is combined with Elocalcitol. |
| Maxacalcitol | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Maxacalcitol. |
| Doxercalciferol | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Doxercalciferol. |
| Vitamin D | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Vitamin D. |
| 1alpha-Hydroxyvitamin D5 | The risk or severity of adverse effects can be increased when Elocalcitol is combined with 1alpha-Hydroxyvitamin D5. |
| Previtamin D(3) | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Previtamin D(3). |
| Calcium acetate | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Calcium acetate. |
| Calcium glucoheptonate | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Calcium glucoheptonate. |
| Calcium chloride | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Calcium chloride. |
| Calcium | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Calcium. |
| Calcium carbonate | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Calcium carbonate. |
| Calcium citrate | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Calcium citrate. |
| Calcium gluconate | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Calcium gluconate. |
| Calcium Phosphate | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Calcium Phosphate. |
| Calcium glubionate anhydrous | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Calcium glubionate anhydrous. |
| Calcium lactate | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Calcium lactate. |
| Calcium lactate gluconate | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Calcium lactate gluconate. |
| Calcium pangamate | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Calcium pangamate. |
| Calcium levulinate | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Calcium levulinate. |
| Calcium cation | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Calcium cation. |
| Calcium polycarbophil | The risk or severity of adverse effects can be increased when Elocalcitol is combined with Calcium polycarbophil. |
| Colestipol | The serum concentration of Elocalcitol can be decreased when it is combined with Colestipol. |
| Sevelamer | The serum concentration of Elocalcitol can be decreased when it is combined with Sevelamer. |
| Colesevelam | The serum concentration of Elocalcitol can be decreased when it is combined with Colesevelam. |
| Cholestyramine | The serum concentration of Elocalcitol can be decreased when it is combined with Cholestyramine. |
| Flunisolide | The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Flunisolide. |
| Beclomethasone dipropionate | The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Beclomethasone dipropionate. |
| Betamethasone | The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Betamethasone. |
| Fluticasone propionate | The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Fluticasone propionate. |
| Fluocinolone acetonide | The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Fluocinolone acetonide. |
| Triamcinolone | The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Triamcinolone. |
| Prednisone | The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Prednisone. |
| Fludrocortisone | The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Fludrocortisone. |
| Hydrocortisone | The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Hydrocortisone. |
| Prednisolone | The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Prednisolone. |
| Methylprednisolone | The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Methylprednisolone. |
| Trilostane | The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Trilostane. |
| Budesonide | The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Budesonide. |
| Dexamethasone | The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Dexamethasone. |
| Corticotropin | The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Corticotropin. |